Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (ECOR) is a leader in non-invasive vagus nerve stimulation therapies, providing innovative solutions for neurological conditions and wellness applications. This page serves as the definitive source for ECOR news, offering investors and professionals timely updates on regulatory developments, clinical research, and strategic initiatives.
Access curated press releases covering FDA clearances, partnership announcements, and financial results. Stay informed about advancements in gammaCore™ therapies for migraine treatment and TAC-STIM cognitive enhancement technologies. Our repository includes updates on international expansions, clinical trial outcomes, and product pipeline developments.
Bookmark this page for direct access to primary source materials from electroCore, including neuromodulation research breakthroughs and commercialization progress across healthcare and defense sectors. Regular updates ensure you maintain current awareness of ECOR's position in the evolving bioelectronic medicine landscape.
electroCore, Inc. (Nasdaq: ECOR) announced positive results from a clinical trial conducted at the Defense Language Institute, demonstrating the effectiveness of non-invasive Vagus Nerve Stimulation (nVNS) in accelerating foreign language learning. The study, published in Scientific Reports, showed that nVNS significantly improved Arabic vocabulary recall compared to sham treatment (p=0.025). Additionally, nVNS participants experienced increased energy (p=0.036) and focus (p=0.001) during training sessions.
The trial involved 36 students from DLI's Arabic school, with 18 receiving nVNS and 18 receiving sham treatment. The nVNS group maintained improved recall even after treatment completion. Dr. Richard McKinley of the Air Force's 711th Human Performance Wing noted that nVNS could be a viable tool to enhance warfighter training and resilience in various areas.
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced that it will release its financial results for the second quarter ended June 30, 2024, after the market closes on Wednesday, August 7, 2024. The company will host a conference call and webcast at 4:30 PM EDT on the same day to discuss the financial results and address questions from investors and analysts.
Interested parties can access the conference call by dialing 877-407-8835 (domestic) or +1 201-689-8779 (international) and using the Conference ID: 13744119. A webcast of the earnings call will also be available for those who prefer to listen online.
electroCore has launched TAC-STIM™, an advanced non-invasive vagus nerve stimulator designed for active-duty military use. The device, developed with the US military, aims to enhance human performance by improving focus, reducing fatigue, and accelerating learning by 20-35%. TAC-STIM is portable and uses electroCore's patented technology for precise vagus nerve stimulation. It has been independently tested by the Air Force Research Laboratory and Air Force Special Operations Command, showing reliable performance in various operational settings. TAC-STIM is now available for wholesale purchase.
electroCore (Nasdaq: ECOR) announced its preliminary inclusion in the Russell Microcap® Index. The newly reconstituted indexes will take effect after the market close on June 28, 2024, and begin trading on July 1, 2024, according to a preliminary list by FTSE Russell posted on May 24, 2024. CFO Brian Posner highlighted that this inclusion could boost the company's exposure to investors. The Russell indexes, used by investment managers and institutional investors, benchmark approximately $10.5 trillion in assets. FTSE Russell, a leading global index provider, oversees these indexes.
electroCore has closed a $9.3M registered direct offering and concurrent private placements. The offering includes 225,000 pre-funded warrants and 112,500 common stock warrants sold to institutional investors, plus 1,208,310 shares and 604,150 warrants sold in separate private placements. Each pre-funded warrant was priced at $6.43, exercisable at $0.001 per share, while shares were priced at $6.43 each. The total gross proceeds are $9.3M, with $5.645M from company directors and officers. Funds are earmarked for sales, marketing, working capital, and general purposes. CEO Dan Goldberger highlights strong revenue momentum and operational leverage, expecting positive cash flow by 2025.
ElectroCore announced a $9.3 million registered direct offering and concurrent private placements. The company will issue pre-funded warrants and common stock shares to institutional and accredited investors. Each share is priced at $6.4925, and accompanying warrants will be exercisable at $6.43 per share for five years. The proceeds will support sales, marketing, working capital, and general corporate activities. The transactions include significant investments from company directors and officers amounting to $5.645 million. The completion of these offerings is expected by June 5, 2024, pending customary closing conditions.
electroCore, Inc. (Nasdaq: ECOR) announced record first quarter 2024 net sales of $5.4 million, a 96% increase over first quarter 2023. The company launched Truvaga Plus, a direct-to-consumer mobile app-enabled product for general wellness. Gross profit for Q1 2024 was $4.6 million with a gross margin of 84%. Operating expenses were $8.4 million with a decrease in R&D expenses and an increase in sales and marketing investments. GAAP net loss improved to $3.5 million, or $0.53 per share, compared to $5.9 million in Q1 2023. Adjusted EBITDA net loss was $3.1 million, down from $5.1 million in Q1 2023. Cash, cash equivalents, and restricted cash as of March 31, 2024, totaled approximately $8.1 million.
electroCore, Inc. announced that Donald Melnikoff joined as SVP, Engineering, Regulatory, and Compliance, with an inducement grant of 10,000 RSUs. The RSUs were granted under NASDAQ Listing Rule 5635(c)(4) and will vest over three years.
electroCore, Inc. (Nasdaq: ECOR) will announce its first quarter financial results on May 8, 2024, after the market closes. The company, specializing in bioelectronic medicine and wellness, will hold a conference call to discuss the results and answer questions.
electroCore, Inc. (NASDAQ: ECOR) announced positive results from its recent Truvaga Plus consumer study, showing improvements in sleep, focus, stress, energy, and mood. 82% felt calmer, 82% mentally healthier, 77% more alert, 77% more relaxed, 74% slept better, 74% mood improved, and 67% had more energy. Users reported between 30 mins to 2+ hours of additional sleep per night. 87% expressed interest in continuing the product for ongoing wellness benefits.
